ZVRA PE Ratio & Valuation,Is ZVRA Overvalued

ZVRA Relative Valuation

ZVRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZVRA is overvalued; if below, it's undervalued.

Historical Valuation

Zevra Therapeutics Inc (ZVRA) is now in the Fair zone, suggesting that its current forward PS ratio of 3.50 is considered Fairly compared with the five-year average of -5.30. The fair price of Zevra Therapeutics Inc (ZVRA) is between 7.01 to 35.16 according to relative valuation methord.

Relative Value

Fair Zone

7.01-35.16

Current Price：8.33

Fair

17.82

11.78

EV/EBITDA

Zevra Therapeutics Inc. (ZVRA) has a current EV/EBITDA of 11.78. The 5-year average EV/EBITDA is -2.70. The thresholds are as follows: Strongly Undervalued below -53.42, Undervalued between -53.42 and -28.06, Fairly Valued between 22.66 and -28.06, Overvalued between 22.66 and 48.03, and Strongly Overvalued above 48.03. The current Forward EV/EBITDA of 11.78 falls within the Historic Trend Line -Fairly Valued range.

10.42

EV/EBIT

Zevra Therapeutics Inc. (ZVRA) has a current EV/EBIT of 10.42. The 5-year average EV/EBIT is 1312.72. The thresholds are as follows: Strongly Undervalued below -31366.99, Undervalued between -31366.99 and -15027.13, Fairly Valued between 17652.58 and -15027.13, Overvalued between 17652.58 and 33992.44, and Strongly Overvalued above 33992.44. The current Forward EV/EBIT of 10.42 falls within the Historic Trend Line -Fairly Valued range.

3.50

Zevra Therapeutics Inc. (ZVRA) has a current PS of 3.50. The 5-year average PS is 9.58. The thresholds are as follows: Strongly Undervalued below -5.21, Undervalued between -5.21 and 2.19, Fairly Valued between 16.98 and 2.19, Overvalued between 16.98 and 24.37, and Strongly Overvalued above 24.37. The current Forward PS of 3.50 falls within the Historic Trend Line -Fairly Valued range.

10.68

P/OCF

Zevra Therapeutics Inc. (ZVRA) has a current P/OCF of 10.68. The 5-year average P/OCF is -2.70. The thresholds are as follows: Strongly Undervalued below -15.82, Undervalued between -15.82 and -9.26, Fairly Valued between 3.86 and -9.26, Overvalued between 3.86 and 10.42, and Strongly Overvalued above 10.42. The current Forward P/OCF of 10.68 falls within the Strongly Overvalued range.

11.75

P/FCF

Zevra Therapeutics Inc. (ZVRA) has a current P/FCF of 11.75. The 5-year average P/FCF is -2.38. The thresholds are as follows: Strongly Undervalued below -29.59, Undervalued between -29.59 and -15.99, Fairly Valued between 11.22 and -15.99, Overvalued between 11.22 and 24.82, and Strongly Overvalued above 24.82. The current Forward P/FCF of 11.75 falls within the Overvalued range.

Zevra Therapeutics Inc (ZVRA) has a current Price-to-Book (P/B) ratio of 3.52. Compared to its 3-year average P/B ratio of 5.17 , the current P/B ratio is approximately -31.88% higher. Relative to its 5-year average P/B ratio of 3.82, the current P/B ratio is about -7.74% higher. Zevra Therapeutics Inc (ZVRA) has a Forward Free Cash Flow (FCF) yield of approximately -5.17%. Compared to its 3-year average FCF yield of -13.41%, the current FCF yield is approximately -61.47% lower. Relative to its 5-year average FCF yield of -7.94% , the current FCF yield is about -34.94% lower.

3.52

P/B

Median3y

5.17

Median5y

3.82

-5.17

FCF Yield

Median3y

-13.41

Median5y

-7.94

Competitors Valuation Multiple

The average P/S ratio for ZVRA's competitors is 6.02, providing a benchmark for relative valuation. Zevra Therapeutics Inc Corp (ZVRA) exhibits a P/S ratio of 3.50, which is -41.8% above the industry average. Given its robust revenue growth of 605.36%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ZVRA decreased by 0.12% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.70M to 26.06M.

The secondary factor is the Margin Expansion, contributed -99.77%to the performance.

Overall, the performance of ZVRA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

605.36%

3.70M → 26.06M

Revenue Growth

-99.77%

-899.19 → -2.09

Margin Expansion

-505.71%

-3.83 → 15.52

P/E Change

-0.12%

8.34 → 8.33

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Zevra Therapeutics Inc (ZVRA) currently overvalued or undervalued?

What is Zevra Therapeutics Inc (ZVRA) fair value?

ZVRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Zevra Therapeutics Inc (ZVRA) is between 7.01 to 35.16 according to relative valuation methord.

How does ZVRA's valuation metrics compare to the industry average?

The average P/S ratio for ZVRA's competitors is 6.02, providing a benchmark for relative valuation. Zevra Therapeutics Inc Corp (ZVRA) exhibits a P/S ratio of 3.50, which is -41.80% above the industry average. Given its robust revenue growth of 605.36%, this premium appears sustainable.

What is the current P/B ratio for Zevra Therapeutics Inc (ZVRA) as of Dec 15 2025?

As of Dec 15 2025, Zevra Therapeutics Inc (ZVRA) has a P/B ratio of 3.52. This indicates that the market values ZVRA at 3.52 times its book value.

What is the current FCF Yield for Zevra Therapeutics Inc (ZVRA) as of Dec 15 2025?

As of Dec 15 2025, Zevra Therapeutics Inc (ZVRA) has a FCF Yield of -5.17%. This means that for every dollar of Zevra Therapeutics Inc’s market capitalization, the company generates -5.17 cents in free cash flow.

What is the current Forward P/E ratio for Zevra Therapeutics Inc (ZVRA) as of Dec 15 2025?

As of Dec 15 2025, Zevra Therapeutics Inc (ZVRA) has a Forward P/E ratio of 17.82. This means the market is willing to pay $17.82 for every dollar of Zevra Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Zevra Therapeutics Inc (ZVRA) as of Dec 15 2025?

As of Dec 15 2025, Zevra Therapeutics Inc (ZVRA) has a Forward P/S ratio of 3.50. This means the market is valuing ZVRA at $3.50 for every dollar of expected revenue over the next 12 months.

ZVRA Valuation